Stay updated on BBI608 Pembrolizumab Combination: Clinical Trial
Sign up to get notified when there's something new on the BBI608 Pembrolizumab Combination: Clinical Trial page.

Latest updates to the BBI608 Pembrolizumab Combination: Clinical Trial page
- Check4 days agoChange DetectedThe study record page now shows a 403 Forbidden message with a Home link. The site revision changed from v3.7.2 to v3.8.0.SummaryDifference0.6%

- Check11 days agoChange DetectedAn NIH announcement banner was added, describing a transition from “Artificial Intelligence” to “Super Intelligence” terminology across NIH content.SummaryDifference1%

- Check18 days agoChange DetectedThe footer’s site revision identifier updates from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check25 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check46 days agoChange DetectedThe study page now presents a 403 Forbidden error, replacing the usual content with an access-denied notice.SummaryDifference19%

- Check67 days agoChange DetectedThe revision tag on the page changed from v3.6.5 to v3.6.6. This indicates a minor page version update rather than changes to the study content.SummaryDifference0.1%

Stay in the know with updates to BBI608 Pembrolizumab Combination: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBI608 Pembrolizumab Combination: Clinical Trial page.